Retraction Note to: Cell Death & Disease https://doi.org/10.1038/cddis.2017.119, published online 18 May 2017
The Editors-in-Chief have retracted this article. Concerns were raised regarding a number of figures, specifically:
-
Figure 2j: the panels for anti-miR-106b and anti-miR-93 appear to partially overlap.
-
Figure 6a: panel 3 (left) and panel 3 (right) for MDA-MB-231 appear to partially overlap.
The Editors-in-Chief therefore no longer have confidence in the reliability of the data reported in the article.
Author Li Jia has stated on behalf of all authors that they disagree with this retraction.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Li, N., Miao, Y., Shan, Y. et al. Retraction Note: MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell Death Dis 17, 266 (2026). https://doi.org/10.1038/s41419-026-08631-2
Published:
Version of record:
DOI: https://doi.org/10.1038/s41419-026-08631-2
